The safety issue with the anti-inflammatory drug ‘Celecoxib’… what are doctors’ opinions?
A COX-2 selective nonsteroidal anti-inflammatory drug ‘Celecoxib’ has got in a safety issue again.
The celecoxib’scardiovascular safety issue has received attention again in the last September 2 when the National Institute of Food and Drug Safety Evaluation (NIFDS) asked to change contents of pe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
